NASDAQ:SRPT

Sarepta Therapeutics Stock News

etoro logo Buy SRPT
*Your capital is at risk
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026

New Strong Buy Stocks for January 3rd

08:16am, Wednesday, 03'rd Jan 2024
GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd
Sarepta (SRPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sarepta Therapeutics recently launched a new medicine. It already has several on the market, but the company isn't yet profitable.
Sarepta (SRPT) files a supplement with the FDA seeking to expand its recently-approved gene therapy Elevidys' label to treat all DMD patients, regardless of age and ambulatory status.
Sarepta Therapeutics and Vertex Pharmaceuticals already have a lot in common. Sarepta's focus market has a few peculiarities that could pose a problem.
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
Sarepta has encountered several issues related to its gene therapy for Duchenne muscular dystrophy. The small biotech is still generating solid financial results and has an extensive pipeline of progr
Sarepta Therapeutics has multiple treatments for Duchenne muscular dystrophy, a rare genetic disorder. Its gene therapy Elevidys obtained accelerated approval this year, but recent data from a clinica
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

3 Monster Stocks in the Making

06:49am, Saturday, 18'th Nov 2023
Beam Therapeutics develops highly promising base-editing therapies. CRISPR Therapeutics could soon have its first product on the market in the U.S. Sarepta Therapeutics is a leader in treating rare ge
The recent surge in official interest rates, the most substantial in 40 years, is anticipated to impact aggregate demand significantly. This could potentially result in a GDP reduction of approximatel
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE